Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
NORTHWEST BIOTHERAPEUTICS INC incurred loan of $11,005,000 with Streeterville Capital, LLC at 8% per annum maturing 24 months.
- Instrument
- loan
- Principal
- $11,005,000
- Counterparty
- Streeterville Capital, LLC
- Rate
- 8% per annum
- Maturity
- 24 months
- Event
- incurrence
Exact text from the filing
On November 10, 2023, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000. The Loan Agreement has a maturity of 24 months. Repayments do not start until November 10, 2024. Following November 10, 2024, the Loan Agreement will be amortized in 12 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
NORTHWEST BIOTHERAPEUTICS INC entered into Commercial Loan Agreement and Note with Streeterville Capital, LLC valued at $11,005,000 (effective 2023-11-10).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Streeterville Capital, LLC
- Value
- $11,005,000
- Effective
- 2023-11-10
Exact text from the filing
On November 10, 2023, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.
View on SEC.gov